Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective.

Front Pharmacol · 2023 · PMC10229795 · PMID 37266153

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Meanwhile, existing evidence indicated that the Chinese economic burden of lung cancer was $25,029 million in 2017, with an increasing trend in the next decade ( Liu et al., 2021 ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.